Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data from Phase 3
Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, advanced AI models, and engineering expertise to accelerate the biopharma lifecycle.
New Jersey's pre-roll market sees remarkable growth, with Verano and Miss Grass leading. Future projections show potential for further expansion, especially with infused pre-rolls.
Britain's Payment Systems Regulator (PSR) found that Visa and Mastercard have increased fees on retailers without improving service quality. Over the past five years, fees rose by over 30%, adding over £250 million to UK business costs. Lawmakers are calling for more stringent oversight as 95% of U.K. card transactions use Visa or Mastercard, leaving businesses with little choice but to absorb the costs.
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by statistically significant results from two Phase 3 trials Primary physician research found
New Construction to Begin in Q2 2024, Expands Bitcoin Mining CapacitySoluna Holdings, Inc. ("Soluna" or the "Company"), (NASDAQ:SLNH), a developer of green data centers for intensive computing applications including